FDA Fast‑Tracks Psychedelic Drugs

The FDA has granted expedited/priority review vouchers for three experimental psychedelic therapies — synthetic psilocybin (Compass Pathways), Usona’s psilocybin program, and Transcend Therapeutics’ methylone for PTSD — accelerating timelines for possible approval within months. The move accompanies other federal signs of liberalizing drug policy (Justice Department easing state‑licensed medical marijuana restrictions) and includes public statements from FDA leadership about urgency for mental‑health treatments. — If regulators approve psychedelic treatments quickly, it could change clinical psychiatry, reshape drug‑policy debates, and trigger conflicts over evidentiary standards, access, and commercialization of psychoactive therapies.